Literature DB >> 11533433

Importance of risk communication and decision making in cardiovascular conditions in older patients: a discussion paper.

N Dudley1.   

Abstract

Atrial fibrillation and aortic stenosis commonly present doctors and patients with difficult decisions about the risks and benefits of treatment options and are both often inappropriately undertreated. Patients may be confused by risk information and doctors may be aware of patients' limitations and use this to manipulate choices to the ones desired by the doctors. This paper examines the importance of risk communication and discusses difficulties that can arise in decision making in these two common cardiovascular conditions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11533433      PMCID: PMC1765741          DOI: 10.1136/qhc.0100019..

Source DB:  PubMed          Journal:  Qual Health Care        ISSN: 0963-8172


  35 in total

Review 1.  Cardiac valve surgery in the octogenarian.

Authors:  R Prêtre; M I Turina
Journal:  Heart       Date:  2000-01       Impact factor: 5.994

2.  Coronary-artery bypass surgery and the brain.

Authors:  O A Selnes; G M McKhann
Journal:  N Engl J Med       Date:  2001-02-08       Impact factor: 91.245

Review 3.  Understanding risk and lessons for clinical risk communication about treatment preferences.

Authors:  A Edwards; G Elwyn
Journal:  Qual Health Care       Date:  2001-09

4.  Aortic stenosis--listen to the patient, look at the valve.

Authors:  C M Otto
Journal:  N Engl J Med       Date:  2000-08-31       Impact factor: 91.245

5.  Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project).

Authors:  M Lamassa; A Di Carlo; G Pracucci; A M Basile; G Trefoloni; P Vanni; S Spolveri; M C Baruffi; G Landini; A Ghetti; C D Wolfe; D Inzitari
Journal:  Stroke       Date:  2001-02       Impact factor: 7.914

6.  Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis.

Authors:  R G Hart; O Benavente; R McBride; L A Pearce
Journal:  Ann Intern Med       Date:  1999-10-05       Impact factor: 25.391

7.  Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness.

Authors:  L Kalra; G Yu; I Perez; A Lakhani; N Donaldson
Journal:  BMJ       Date:  2000-05-06

8.  The impact of patients' preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis.

Authors:  J Protheroe; T Fahey; A A Montgomery; T J Peters
Journal:  BMJ       Date:  2000-05-20

Review 9.  The extent of patients' understanding of the risk of treatments.

Authors:  A J Lloyd
Journal:  Qual Health Care       Date:  2001-09

10.  Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation.

Authors:  B F Gage; M Boechler; A L Doggette; G Fortune; G C Flaker; M W Rich; M J Radford
Journal:  Stroke       Date:  2000-04       Impact factor: 7.914

View more
  6 in total

Review 1.  Understanding risk and lessons for clinical risk communication about treatment preferences.

Authors:  A Edwards; G Elwyn
Journal:  Qual Health Care       Date:  2001-09

Review 2.  The extent of patients' understanding of the risk of treatments.

Authors:  A J Lloyd
Journal:  Qual Health Care       Date:  2001-09

Review 3.  Informed consent: moral necessity or illusion?

Authors:  L Doyal
Journal:  Qual Health Care       Date:  2001-09

4.  Understanding patients' preferences for treatment: the need for innovative methodologies.

Authors:  L J Frewer; B Salter; N Lambert
Journal:  Qual Health Care       Date:  2001-09

5.  Comparison of two methods of presenting risk information to patients about the side effects of medicines.

Authors:  P Knapp; D K Raynor; D C Berry
Journal:  Qual Saf Health Care       Date:  2004-06

6.  Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomised trial.

Authors:  Danielle E Clarkesmith; Helen M Pattison; Gregory Y H Lip; Deirdre A Lane
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.